What is Confo Therapeutics?
Confo Therapeutics is a clinical-stage biopharmaceutical company at the forefront of discovering novel medicines that target G-protein coupled receptors (GPCRs). Leveraging its proprietary discovery platform, the company excels in identifying and developing small molecules and antibodies designed to achieve specific pharmacological outcomes. This focus on GPCRs, a critical class of drug targets, positions Confo Therapeutics to address a wide range of unmet medical needs across various therapeutic areas.
How much funding has Confo Therapeutics raised?
Confo Therapeutics has raised a total of $98.4M across 2 funding rounds:
Series A
$33.4M
Series B
$65M
Series A (2019): $33.4M, investors not publicly disclosed
Series B (2024): $65M led by Driehaus Capital Management, Ackermans & Van Haaren, and Quest for Growth
Key Investors in Confo Therapeutics
Driehaus Capital Management
Driehaus Capital Management, established in 1982, is an investment management firm based in Chicago, Illinois, likely contributing its expertise in capital allocation and financial strategy to Confo Therapeutics' growth.
Ackermans & Van Haaren
Ackermans & Van Haaren, a Belgian holding company founded in 1876, brings a diversified industrial and financial background, with interests spanning marine engineering, private banking, real estate, energy, and growth capital, indicating a strategic interest in long-term value creation.
Quest for Growth
Quest for Growth Belgium, a mutual fund managed by Quest Management NV since 1998, specializes in investing in European growth stocks, particularly in technology and healthcare sectors, suggesting a focus on innovative companies with high-potential pipelines like Confo Therapeutics.
What's next for Confo Therapeutics?
With the recent major strategic investment, Confo Therapeutics is poised to accelerate its clinical development pipeline and further enhance its discovery platform. This substantial capital infusion is expected to fuel the progression of its drug candidates through clinical trials, potentially leading to significant milestones in the near future. The company's strategic focus on GPCRs, combined with its advanced technological capabilities, suggests a trajectory aimed at bringing innovative therapies to patients and solidifying its position as a leader in targeted drug discovery.
See full Confo Therapeutics company page
